Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Arbutus BiopharmaGalera TherapeuticsAmpio PharmaceuticalsKamadaNabriva Therapeutics
SymbolNASDAQ:ABUSNASDAQ:GRTXNYSEAMERICAN:AMPENASDAQ:KMDANASDAQ:NBRV
Price Information
Current Price$3.30$8.06$1.82$6.14$1.66
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.41.61.31.41.3
Analysis Score3.43.53.53.53.3
Community Score2.82.12.52.22.7
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.00.0
Earnings & Valuation Score0.60.60.61.30.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$6.50$17.00$4.00$11.00$6.00
% Upside from Price Target96.97% upside110.92% upside119.78% upside79.15% upside261.45% upside
Trade Information
Market Cap$315.43 million$201.31 million$356.05 million$273.35 million$415.41 million
Beta3.151.891.791.11.91
Average Volume2,523,28766,5213,571,602212,7292,118,854
Sales & Book Value
Annual Revenue$6.01 millionN/AN/A$127.19 million$9.48 million
Price / Sales52.48N/AN/A2.1543.82
CashflowN/AN/AN/A$0.52 per shareN/A
Price / CashN/AN/AN/A11.74N/A
Book Value($1.00) per share$2.81 per share$0.04 per share$3.04 per share$0.44 per share
Price / Book-3.30N/AN/A2.023.77
Profitability
Net Income$-153,720,000.00$-51,930,000.00$-13,630,000.00$22.25 million$-82,760,000.00
EPS($1.62)($16.31)($0.14)$0.55($11.20)
Trailing P/E RatioN/AN/AN/A12.79N/A
Forward P/E RatioN/AN/AN/A55.82N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-1,163.48%N/AN/A15.60%-1,682.55%
Return on Equity (ROE)N/A-151.01%-192.88%12.89%-129.80%
Return on Assets (ROA)-59.66%-60.72%-97.89%10.66%-71.67%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.21%
Current Ratio15.94%8.79%5.65%7.52%4.95%
Quick Ratio15.94%8.79%5.65%5.69%4.42%
Ownership Information
Institutional Ownership Percentage28.44%75.41%9.91%14.25%23.70%
Insider Ownership Percentage6.70%19.30%3.60%N/A2.76%
Miscellaneous
Employees763223408162
Shares Outstanding95.58 million24.98 million195.63 million44.52 million250.25 million
Next Earnings Date5/10/2021 (Estimated)5/11/2021 (Estimated)5/5/2021 (Estimated)5/17/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Syndaxs (SNDX) Axatilimab Gets FDAs Orphan Drug Tag for IPFSyndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF
finance.yahoo.com - April 9 at 11:11 AM
 Brokerages Expect Nabriva Therapeutics plc (NASDAQ:NBRV) Will Post Quarterly Sales of $1.46 Million Brokerages Expect Nabriva Therapeutics plc (NASDAQ:NBRV) Will Post Quarterly Sales of $1.46 Million
americanbankingnews.com - April 8 at 1:12 AM
Nabriva Therapeutics plc (NASDAQ:NBRV) Expected to Announce Earnings of -$0.57 Per ShareNabriva Therapeutics plc (NASDAQ:NBRV) Expected to Announce Earnings of -$0.57 Per Share
americanbankingnews.com - April 7 at 12:08 AM
Nabriva Therapeutics plc (NASDAQ:NBRV) Short Interest UpdateNabriva Therapeutics plc (NASDAQ:NBRV) Short Interest Update
americanbankingnews.com - April 1 at 3:20 PM
Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare ConferenceNabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 1 at 12:27 PM
Nabriva Therapeutics plc (NASDAQ:NBRV) Stock: Up 19.08% Since Low, This Stock Is Just Getting Warmed UpNabriva Therapeutics plc (NASDAQ:NBRV) Stock: Up 19.08% Since Low, This Stock Is Just Getting Warmed Up
stocksregister.com - March 29 at 8:12 AM
Nabriva Therapeutics plc (NASDAQ:NBRV) Has Recovered 16.02% So Far, But Another 562.98% Gain Cannot Be Ruled OutNabriva Therapeutics plc (NASDAQ:NBRV) Has Recovered 16.02% So Far, But Another 562.98% Gain Cannot Be Ruled Out
marketingsentinel.com - March 26 at 2:34 PM
Nabriva Therapeutics plc (NASDAQ:NBRV) Expected to Post Quarterly Sales of $1.46 MillionNabriva Therapeutics plc (NASDAQ:NBRV) Expected to Post Quarterly Sales of $1.46 Million
americanbankingnews.com - March 22 at 1:48 AM
-$0.63 EPS Expected for Nabriva Therapeutics plc (NASDAQ:NBRV) This Quarter-$0.63 EPS Expected for Nabriva Therapeutics plc (NASDAQ:NBRV) This Quarter
americanbankingnews.com - March 20 at 4:08 PM
Nabriva Therapeutics (NASDAQ:NBRV) Shares Gap Up to $1.92Nabriva Therapeutics (NASDAQ:NBRV) Shares Gap Up to $1.92
americanbankingnews.com - March 17 at 10:51 AM
NBRV Stock Price Increases Over 15% Pre-Market: Why It HappenedNBRV Stock Price Increases Over 15% Pre-Market: Why It Happened
pulse2.com - March 17 at 8:44 AM
Nabriva Therapeutics (NASDAQ:NBRV)  Shares Down 8.6% Nabriva Therapeutics (NASDAQ:NBRV) Shares Down 8.6%
americanbankingnews.com - March 16 at 7:56 PM
Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)
finance.yahoo.com - March 16 at 12:16 PM
Nabriva Therapeutics PLC (NBRV) CEO Theodore Schroeder on Q4 2020 Results - Earnings Call TranscriptNabriva Therapeutics PLC (NBRV) CEO Theodore Schroeder on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 13 at 3:58 PM
Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides ...Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides ...
apnews.com - March 12 at 7:55 PM
Northland Securities Trims Nabriva Therapeutics (NASDAQ:NBRV) Target Price to $6.00Northland Securities Trims Nabriva Therapeutics (NASDAQ:NBRV) Target Price to $6.00
marketbeat.com - March 12 at 8:19 AM
Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March ...Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March ...
apnews.com - March 4 at 9:56 AM
Nabriva Therapeutics plans to raise $25.4M through stock saleNabriva Therapeutics plans to raise $25.4M through stock sale
bizjournals.com - March 4 at 12:26 AM
Why Nabriva Therapeuticss Stock is Trading Lower TodayWhy Nabriva Therapeutics's Stock is Trading Lower Today
msn.com - March 1 at 1:26 PM
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market ...Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market ...
apnews.com - March 1 at 8:25 AM
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesNabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
finance.yahoo.com - March 1 at 8:25 AM
Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial OfficerNabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
finance.yahoo.com - February 26 at 11:19 AM
Nabriva Therapeutics announces CFO retirementNabriva Therapeutics announces CFO retirement
seekingalpha.com - February 3 at 12:36 AM
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer - Seite 2Nabriva Therapeutics Announces Retirement of its Chief Financial Officer - Seite 2
wallstreet-online.de - February 1 at 6:41 PM
Nabriva Therapeutics Announces Retirement of its Chief Financial OfficerNabriva Therapeutics Announces Retirement of its Chief Financial Officer
finance.yahoo.com - February 1 at 6:41 PM
Nabriva Gets Initial Nod For $3M Investor SettlementNabriva Gets Initial Nod For $3M Investor Settlement
law360.com - January 29 at 5:34 PM
DateCompanyBrokerageAction
3/10/2021Arbutus BiopharmaB. RileyLower Price Target
3/10/2021Arbutus BiopharmaHC WainwrightReiterated Rating
2/25/2021Arbutus BiopharmaJefferies Financial GroupInitiated Coverage
11/16/2020Arbutus BiopharmaChardan CapitalReiterated Rating
7/27/2020Arbutus BiopharmaJMP SecuritiesInitiated Coverage
7/24/2020Arbutus BiopharmaRobert W. BairdDowngrade
5/19/2020Arbutus BiopharmaWedbushUpgrade
10/4/2019Arbutus BiopharmaEchelon Wealth PartnersDowngrade
12/16/2020Galera TherapeuticsCredit Suisse GroupUpgrade
10/28/2020Galera TherapeuticsSmith Barney CitigroupBoost Price Target
12/2/2019Galera TherapeuticsBTIG ResearchInitiated Coverage
12/2/2019Galera TherapeuticsCitigroupInitiated Coverage
12/2/2019Galera TherapeuticsBank of AmericaInitiated Coverage
1/22/2021Ampio PharmaceuticalsRoth CapitalReiterated Rating
3/12/2021Nabriva TherapeuticsNorthland SecuritiesLower Price Target
4/8/2020Nabriva TherapeuticsNeedham & Company LLCDowngrade
3/17/2020Nabriva TherapeuticsMorgan StanleyDowngrade
5/2/2019Nabriva TherapeuticsGabelliUpgrade
(Data available from 4/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.